Mixed data for Renovo's scarring therapy
Renovo's Juvista produced a mixed set of data in two mid-stage trials. The drug produced positive data in reducing scarring but failed to demonstrate efficacy during a breast augmentation trial. Researchers also said that the therapy was more effective against scarring when administered twice and noted that during the breast augmentation trial the drug was administered once. Renovo plans to launch a Phase III trial of Juvista in the second half of this year. Shire, a partner on the drug, agreed to invest $75 million in Juvista, plus make a $50 million equity investment in Renovo.
"Shire is at present assessing these latest results with all other results produced to date and plans to discuss these with the FDA in 2008 to determine the regulatory path forward in the United States," said Renovo in a statement.
- read the press release for more information
Related Articles:
Renovo inks $875M deal for scarring drug. Report
Renovo CEO bullish on partnership prospects. Report
Renovo sees shares jump on first day. Report
Comments (1) | Post a comment
Comments
By Anonymous | Posted 8:39am | March 4, 2008
Interestind data. It makes me cringe to think of intradermal injection 24hrs after sugery along the line of the incision!. Yuk! Have they looked at wound infections? How have they chosen 500ng after looking at only 50 and 200ng in Phase 2. Look at 500ng with intersting results!!
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
